{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:46:52Z","timestamp":1764701212232,"version":"3.44.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007693","name":"King Chulalongkorn Memorial Hospital","doi-asserted-by":"publisher","award":["HA-64-3300-21-024"],"award-info":[{"award-number":["HA-64-3300-21-024"]}],"id":[{"id":"10.13039\/100007693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This randomized, double-blind, sham-controlled trial aimed to evaluate the novel quantum molecular resonance (QMR) device for meibomian gland dysfunction (MGD) treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eighty participants diagnosed with MGD were randomized into QMR or sham-QMR groups. Each procedure was performed on days 0, 7, 14, and 21. Primary (meibum quality score) and other secondary outcomes were examined at baseline and weeks 7 and 11. Tear osmolarity and interleukin (IL)-6 and IL-1 receptor agonist levels were evaluated at baseline and week 7. Adverse events were recorded. A multilevel mixed-effect linear regression model was used for data analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Meibum quality (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), corneal\/conjunctival fluorescein staining score (<jats:italic>p<\/jats:italic>\u2009=\u20090.036), telangiectatic vessel area (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), and superior (<jats:italic>p<\/jats:italic>\u2009=\u20090.011) and inferior (<jats:italic>p<\/jats:italic>\u2009=\u20090.020) lid meiboscale were significantly improved in the QMR group than those in the sham-treated group at week 11. Superior lid meiboscale (<jats:italic>p<\/jats:italic>\u2009=\u20090.027) and meibomian gland plugging grade (MGPG) (<jats:italic>p<\/jats:italic>\u2009=\u20090.017) were significantly improved in the QMR group at week 7. In the QMR group, Ocular Surface Disease Index (OSDI) scores and lid margin thickening grades were significantly lesser at weeks 7 (<jats:italic>p<\/jats:italic>\u2009=\u20090.002 and &lt;0.001, respectively) and 11 (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) than the baseline values. At week 7, IL-6 levels were significantly decreased only in the QMR group (<jats:italic>p<\/jats:italic>\u2009=\u20090.016). All other parameters did not significantly differ. No serious adverse event occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The QMR device was effective for MGD treatment, with improvements in meibum quality, corneal\/conjunctival staining, telangiectatic vessels, MGPG, superior and inferior lid meiboscale, and decreased OSDI score, lid margin thickening grade, and tear IL-6 level.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03890-3","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:44:10Z","timestamp":1751010250000},"page":"2451-2459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized, double-masked, sham-controlled trial of efficacy and safety of quantum molecular resonance for treating meibomian gland dysfunction"],"prefix":"10.1038","volume":"39","author":[{"given":"Lita","family":"Uthaithammarat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1926-4666","authenticated-orcid":false,"given":"Ngamjit","family":"Kasetsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3660-3538","authenticated-orcid":false,"given":"Usanee","family":"Reinprayoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuda","family":"Chongpison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiyada","family":"Quanchareonsap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paphaphat","family":"Dissaneevate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"3890_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","volume":"52","author":"E Knop","year":"2011","unstructured":"Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938\u201378.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR2","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O\u2019Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050\u201364.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR3","doi-asserted-by":"crossref","unstructured":"Trivli A, Karmiris E, Dalianis G, Ruggeri A, Terzidou C. Evaluating the efficacy of Quantum Molecular Resonance (QMR) electrotherapy in mixed-type dry eye patients. J Optom. 2022;16:128\u201334.","DOI":"10.1016\/j.optom.2022.06.003"},{"key":"3890_CR4","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/ICO.0000000000002063","volume":"38","author":"G Ferrari","year":"2019","unstructured":"Ferrari G, Colucci A, Barbariga M, Ruggeri A, Rama P. High frequency electrotherapy for the treatment of meibomian gland dysfunction. Cornea. 2019;38:1424\u20139.","journal-title":"Cornea"},{"key":"3890_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/bjophthalmol-2016-308678","volume":"101","author":"E Pedrotti","year":"2017","unstructured":"Pedrotti E, Bosello F, Fasolo A, Frigo AC, Marchesoni I, Ruggeri A, et al. Transcutaneous periorbital electrical stimulation in the treatment of dry eye. Br J Ophthalmol. 2017;101:814\u20139.","journal-title":"Br J Ophthalmol"},{"key":"3890_CR6","volume":"15","author":"D Kavroulaki","year":"2023","unstructured":"Kavroulaki D, Konstantinidou E, Tsiogka A, Rallis K, Mavrikakis E. Quantum molecular resonance electrical stimulation as a beneficial and safe treatment for multifactorial dry eye disease. Cureus. 2023;15:e39695.","journal-title":"Cureus"},{"key":"3890_CR7","doi-asserted-by":"crossref","unstructured":"Foo VHX, Liu Y-C, Tho B, Tong L. Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population. Front Med. 2023;10.","DOI":"10.3389\/fmed.2023.1209886"},{"key":"3890_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/ICO.0000000000002204","volume":"39","author":"Y Piyacomn","year":"2020","unstructured":"Piyacomn Y, Kasetsuwan N, Reinprayoon U, Satitpitakul V, Tesapirat L. Efficacy and safety of intense pulsed light in patients with meibomian gland dysfunction-a randomized, double-masked, sham-controlled clinical trial. Cornea. 2020;39:325\u201332.","journal-title":"Cornea"},{"key":"3890_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/bmj.330.7495.843","volume":"330","author":"DG Altman","year":"2005","unstructured":"Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005;330:843.","journal-title":"BMJ"},{"key":"3890_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/iwj.12805","volume":"14","author":"M Fraccalvieri","year":"2017","unstructured":"Fraccalvieri M, Salomone M, Di Santo C, Ruka E, Morozzo U, Bruschi S. Quantum molecular resonance technology in hard-to-heal extremity wounds: histological and clinical results. Int Wound J. 2017;14:1313\u201322.","journal-title":"Int Wound J"},{"key":"3890_CR11","doi-asserted-by":"crossref","unstructured":"Yao G, Kang L, Li C, Chen S, Wang Q, Yang J, et al. A self-powered implantable and bioresorbable electrostimulation device for biofeedback bone fracture healing. Proc Natl Acad Sci USA. 2021;118.","DOI":"10.1073\/pnas.2100772118"},{"key":"3890_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.11.10.17","volume":"11","author":"YS Yoo","year":"2022","unstructured":"Yoo YS, Park S, Eun P, Park YM, Lim DH, Chung TY. Corneal neuro-regenerative effect of transcutaneous electrical stimulation in rabbit lamellar keratectomy model. Transl Vis Sci Technol. 2022;11:17.","journal-title":"Transl Vis Sci Technol"},{"key":"3890_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6548554","volume":"2021","author":"F Sanie-Jahromi","year":"2021","unstructured":"Sanie-Jahromi F, Azizi A, Shariat S, Johari M. Effect of electrical stimulation on ocular cells: a means for improving ocular tissue engineering and treatments of eye diseases. Biomed Res Int. 2021;2021:6548554.","journal-title":"Biomed Res Int"},{"key":"3890_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/bjophthalmol-2012-302668","volume":"97","author":"R Arita","year":"2013","unstructured":"Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725\u20139.","journal-title":"Br J Ophthalmol"},{"key":"3890_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/bjophthalmol-2016-310097","volume":"102","author":"SL Maskin","year":"2018","unstructured":"Maskin SL, Testa WR. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2018;102:59\u201368.","journal-title":"Br J Ophthalmol"},{"key":"3890_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/ICO.0000000000001042","volume":"36","author":"Y Yin","year":"2017","unstructured":"Yin Y, Gong L. Reversibility of gland dropout and significance of eyelid hygiene treatment in meibomian gland dysfunction. Cornea. 2017;36:332\u20137.","journal-title":"Cornea"},{"key":"3890_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100242","volume":"3","author":"G Han","year":"2023","unstructured":"Han G, Lim DH, Yoo YS, Shin EH, Park JY, Kim D, et al. Transcutaneous electrical stimulation for the prevention of dry eye disease after photorefractive keratectomy: randomized controlled trial. Ophthalmol Sci. 2023;3:100242.","journal-title":"Ophthalmol Sci"},{"key":"3890_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/etm.2020.9305","volume":"20","author":"MM Cai","year":"2020","unstructured":"Cai MM, Zhang J. Effectiveness of transcutaneous electrical stimulation combined with artificial tears for the treatment of dry eye: a randomized controlled trial. Exp Ther Med. 2020;20:175.","journal-title":"Exp Ther Med"},{"key":"3890_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539\u201374.","journal-title":"Ocul Surf"},{"key":"3890_CR20","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s10792-023-02721-2","volume":"43","author":"J Feng","year":"2023","unstructured":"Feng J, Wang J, Wu B, Shao Q, Zang Y, Cao K, et al. Association of meibomian gland morphology with orifice plugging and lid margin thickening in meibomian gland dysfunction patients. Int Ophthalmol. 2023;43:3207\u201318.","journal-title":"Int Ophthalmol"},{"key":"3890_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2020.151609","volume":"233","author":"M Br\u00fcndl","year":"2021","unstructured":"Br\u00fcndl M, Garreis F, Schicht M, Dietrich J, Paulsen F. Characterization of the innervation of the meibomian glands in humans, rats and mice. Ann Anat. 2021;233:151609.","journal-title":"Ann Anat"},{"key":"3890_CR22","doi-asserted-by":"publisher","first-page":"e0190082","DOI":"10.1371\/journal.pone.0190082","volume":"13","author":"S Sella","year":"2018","unstructured":"Sella S, Adami V, Amati E, Bernardi M, Chieregato K, Gatto P, et al. In-vitro analysis of quantum molecular resonance effects on human mesenchymal stromal cells. PLoS ONE. 2018;13:e0190082.","journal-title":"PLoS ONE"},{"key":"3890_CR23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/ICO.0000000000001916","volume":"38","author":"S Yang","year":"2019","unstructured":"Yang S, Lee HJ, Kim DY, Shin S, Barabino S, Chung SH. The use of conjunctival staining to measure ocular surface inflammation in patients with dry eye. Cornea. 2019;38:698\u2013705.","journal-title":"Cornea"},{"key":"3890_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ajo.2019.09.005","volume":"209","author":"J Xiao","year":"2020","unstructured":"Xiao J, Adil MY, Chen X, Utheim \u00d8A, R\u00e6der S, T\u00f8nseth KA, et al. Functional and morphological evaluation of meibomian glands in the assessment of meibomian gland dysfunction subtype and severity. Am J Ophthalmol. 2020;209:160\u20137.","journal-title":"Am J Ophthalmol"},{"key":"3890_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54013-4","volume":"9","author":"J Xiao","year":"2019","unstructured":"Xiao J, Adil MY, Olafsson J, Chen X, Utheim \u00d8A, R\u00e6der S, et al. Diagnostic test efficacy of meibomian gland morphology and function. Sci Rep. 2019;9:17345.","journal-title":"Sci Rep"},{"key":"3890_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/OPTH.S89700","volume":"9","author":"JD Bartlett","year":"2015","unstructured":"Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: a systematic review. Clinical Ophthalmol. 2015;9:1719\u201330.","journal-title":"Clinical Ophthalmol"},{"key":"3890_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.joco.2018.05.002","volume":"30","author":"S Kyei","year":"2018","unstructured":"Kyei S, Dzasimatu SK, Asiedu K, Ayerakwah PA. Association between dry eye symptoms and signs. J Curr Ophthalmol. 2018;30:321\u20135.","journal-title":"J Curr Ophthalmol"},{"key":"3890_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/ICL.0000000000000218","volume":"42","author":"SN Onwubiko","year":"2016","unstructured":"Onwubiko SN, Eze BI, Udeh NN, Onwasigwe EN, Umeh RE. Dry eye disease: concordance between the diagnostic tests in African eyes. Eye Contact Lens. 2016;42:395\u2013400.","journal-title":"Eye Contact Lens"},{"key":"3890_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/OPTH.S33588","volume":"6","author":"C Unlu","year":"2012","unstructured":"Unlu C, Guney E, Akcay BI, Akcali G, Erdogan G, Bayramlar H. Comparison of ocular-surface disease index questionnaire, tearfilm break-up time, and Schirmer tests for the evaluation of the tearfilm in computer users with and without dry-eye symptomatology. Clinical Ophthalmol. 2012;6:1303\u20136.","journal-title":"Clinical Ophthalmol"},{"key":"3890_CR30","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s10792-020-01489-z","volume":"40","author":"X Wu","year":"2020","unstructured":"Wu X, Chen X, Ma Y, Lin X, Yu X, He S, et al. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. Int Ophthalmol. 2020;40:3049\u201358.","journal-title":"Int Ophthalmol"},{"key":"3890_CR31","first-page":"862","volume":"16","author":"A Enr\u00edquez-de-Salamanca","year":"2010","unstructured":"Enr\u00edquez-de-Salamanca A, Castellanos E, Stern ME, Fern\u00e1ndez I, Carre\u00f1o E, Garc\u00eda-V\u00e1zquez C, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862\u201373.","journal-title":"Mol Vis"},{"key":"3890_CR32","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1167\/iovs.08-2476","volume":"50","author":"S Chotikavanich","year":"2009","unstructured":"Chotikavanich S, de Paiva CS, Li de Q, Chen JJ, Bian F, Farley WJ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50:3203\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR33","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438\u2013510.","journal-title":"Ocul Surf"},{"key":"3890_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","volume":"100","author":"C Baudouin","year":"2016","unstructured":"Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Ben\u00edtez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3890_CR35","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.12659\/MSM.912010","volume":"24","author":"H Zhao","year":"2018","unstructured":"Zhao H, Li Q, Ye M, Yu J. Tear Luminex analysis in dry eye patients. Med Sci Monit. 2018;24:7595\u2013602.","journal-title":"Med Sci Monit"},{"key":"3890_CR36","first-page":"2283","volume":"42","author":"A Solomon","year":"2001","unstructured":"Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283\u201392.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtos.2019.01.004","volume":"17","author":"C Begley","year":"2019","unstructured":"Begley C, Caffery B, Chalmers R, Situ P, Simpson T, Nelson JD. Review and analysis of grading scales for ocular surface staining. Ocul Surf. 2019;17:208\u201320.","journal-title":"Ocul Surf"},{"key":"3890_CR38","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2147\/DDDT.S146556","volume":"12","author":"X Jiang","year":"2018","unstructured":"Jiang X, Wang Y, Lv H, Liu Y, Zhang M, Li X. Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity. Drug Des Dev Ther. 2018;12:1269\u201379.","journal-title":"Drug Des Dev Ther"},{"key":"3890_CR40","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1167\/iovs.16-21362","volume":"58","author":"M Brinton","year":"2017","unstructured":"Brinton M, Kossler AL, Patel ZM, Loudin J, Franke M, Ta CN, et al. Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci. 2017;58:2341\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3890_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ajo.2016.06.025","volume":"169","author":"R Arita","year":"2016","unstructured":"Arita R, Minoura I, Morishige N, Shirakawa R, Fukuoka S, Asai K, et al. Development of definitive and reliable grading scales for meibomian gland dysfunction. Am J Ophthalmol. 2016;169:125\u201337.","journal-title":"Am J Ophthalmol"},{"key":"3890_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtos.2020.11.007","volume":"19","author":"M Ha","year":"2021","unstructured":"Ha M, Kim JS, Hong SY, Chang DJ, Whang WJ, Na KS, et al. Relationship between eyelid margin irregularity and meibomian gland dropout. Ocul Surf. 2021;19:31\u201337.","journal-title":"Ocul Surf"},{"key":"3890_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ICL.0000000000000680","volume":"46","author":"PY Lam","year":"2020","unstructured":"Lam PY, Shih KC, Fong PY, Chan TCY, Ng AL, Jhanji V, et al. A review on evidence-based treatments for meibomian gland dysfunction. Eye Contact Lens. 2020;46:3\u201316.","journal-title":"Eye Contact Lens"},{"key":"3890_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/02713680802018419","volume":"33","author":"IA Butovich","year":"2008","unstructured":"Butovich IA, Millar TJ, Ham BM. Understanding and analyzing meibomian lipids-a review. Curr Eye Res. 2008;33:405\u201320.","journal-title":"Curr Eye Res"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03890-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03890-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03890-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:35:02Z","timestamp":1757208902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03890-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03890-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}